| 标题 |
FDA panel votes against omapatrilat for hypertension
|
| 网址 |
求助人暂未提供
|
| DOI |
暂未提供，该求助的时间将会延长，查看原因？
|
| 其它 |
Mon, 22 Jul 2002 19:00:00 Bethesda, MD - In a 5-1 vote, the Cardiovascular and Renal Drugs Advisory Committee to the FDA recommended against approval of Bristol-Myers Squibb's (BMS) vasopeptidase inhibitor omapatrilat (Vanlev®) for the treatment of hypertension. The panel was unconvinced that BMS had provided sufficient evidence that the antihypertensive benefit outweighed the high risk of angioedema. It did, however, leave open the option that the company could convince it in the future. |
| 求助人 | |
| 下载 | 暂无链接，等待应助者上传 |
PDF的下载单位、IP信息已删除
(2025-6-4)
22336
cdercder
Copyright
Kao
ale
行走的荷尔蒙
嘉心糖
yjh123
arniu2008
乐空思
昏睡的蟠桃
sagitar
Nole
MozzieMiao
啵啵
舒适的向南
pokexuejiao
aaaa
Oracle
挖掘机
皖公网安备34019202002308
